An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Exclusion Criteria

• •Participants with Ulcerative Colitis (UC) or indeterminate colitis
• •Participants with two entire missing segments of the: terminal ileum, right colon transverse colon, sigmoid and left colon, and rectum
• •Prior or current high-grade gastrointestinal (GI) dysplasia
• •Participants on treatment with but not on stable doses of conventional therapy prior to baseline
• •Participants receiving prohibited medications or therapies
• •Participants with previous exposure to anti-TL1A investigational therapy
• •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.